蛋白酶体抑制剂——硼替佐米在侵袭性恶性淋巴瘤治疗中的应用
摘要
蛋白酶体是一种26S多价催化蛋白酶复合物，广泛存在于真核细胞的核内和细胞质内，是泛素-蛋白酶体通路的主要组成部分。“泛素-蛋白酶体通路”的发现获得了2004年诺贝尔化学奖，湿示了蛋白酶体研究的重要性。泛素-蛋白酶体通路是生物体内进行蛋白质选择性降解的重要途径之一。细胞内调控细胞周期、激活转录因子、调节凋亡等的多种蛋白质，
出处
《药学与临床研究》
2010年第2期104-106,共3页
Pharmaceutical and Clinical Research
参考文献24
-
1Zavrski I,Kleeberg L,KaiserM,et al.Proteasome as an emerging therapeutic target in cancer[J].Curr Pharm Des,2007,13(5):471-85.
-
2Schubert U,Antón LC,Gibbs J,et al.Rapid degradation of a large fraction of newly synthesized proteins by proteasomes[J].Nature,2000,404(6779):770-4.
-
3Richardson PG,Barlogie B,Berenson J,et al.A phase 2 study of Bortezomib in relapsed,refractory myeloma[J].N Engl J Med,2003,348(26):2609-17.
-
4Dimopoulos MA,Richardson PG,Schlag R,et al.VMP (Bortezomib,Melphalan,and Prednisone) is active and well tolerated in newly diagnosed patients with multiple myeloma with moderately impaired renal function,and results in reversal of renal impairment:cohort analysis of the phase III VISTA study[J].J Clin Oncol,2009,27(36):6086-93.
-
5Davies FE,Wu P,Jenner M,et al.The combination of cyclophosphamide,velcade and dexamethasone induces high response rates with comparable toxicity to velcade alone and velcade plus dexamethasone[J].Haematologica,2007,92(8):1149-50.
-
6Goy A,Younes A,McLaughlin P,et al.Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma[J].J Clin Oncol,2005,23(4):667-75.
-
7O'Connor OA,Wright J,Moskowitz C,et al.Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma[J].J Clin Oncol,2005,23(4):676-84.
-
8Gerecitano J,Portlock C,Moskowitz C,et al.Phase 2 study of weekly bortezomib in mantle cell and follicular lymphoma[J].Br J Haematol,2009,146(6):652-5.
-
9Strauss SJ,Maharaj L,Hoare S,et al.Bortezomib therapy in patients with relapsed or refractory lymphoma:potential correlation of in vitro sensitivity and tumor necrosis factor alpha response with clinical activity[J].J Clin Oncol,2006,24(13):2105-12.
-
10Belch A,Kouroukis CT,Crump M,et al.A phase II study of bortezomib in mantle cell lymphoma:the National Cancer Institute of Canada Clinical Trials Group trial IND.150[J].Ann Oncol,2007,18(1):116-21.
-
1张卫国,吴清明,王小虎,谢国建,童强,于皆平.阻断泛素-蛋白酶体通路对胃癌细胞株SGC-7901 DNA合成及细胞周期的影响[J].中国医师杂志,2004,6(2):212-214. 被引量：2
-
2张慧平,李晓明,路秀英.泛素-蛋白酶体通路与头颈肿瘤[J].国际耳鼻咽喉头颈外科杂志,2010,34(3):155-158.
-
3岂连鹏,高玉环.足叶乙甙在恶性淋巴瘤治疗中的应用[J].中华血液学杂志,1993,14(6):316-317.
-
4肖卫国.恶性淋巴瘤治疗中的耐药机制[J].日本医学介绍,1995,16(7):306-307.
-
5李业楠（综述）,邱录贵（审校）.氟达拉滨在侵袭性淋巴瘤中的应用[J].国际输血及血液学杂志,2007,30(1):83-86.
-
6伍钢.放射治疗在恶性淋巴瘤治疗中的地位[J].中华肿瘤防治杂志,2009,16(16):1201-1205. 被引量：5
-
7孙健冰,林丽,刘莲卿.CIK细胞免疫治疗恶性淋巴瘤31例护理[J].福建医药杂志,2010,32(3):146-147. 被引量：8
-
8江千里,孟凡义.肿瘤治疗新靶点:蛋白酶体抑制剂的基础和临床应用[J].中华医学杂志,2005,85(29):2085-2088. 被引量：3
-
9兰雨,杨平地.泛素-蛋白酶体通路在凋亡调控中的作用[J].国外医学（输血及血液学分册）,2001,24(3):204-206. 被引量：5
-
10曾德余,殷先利,李俊军,杨剑锋,李勇.泛素连接酶PIRH2和p53蛋白在胃癌中的表达关系及意义[J].中国肿瘤临床与康复,2010,17(4):331-334.
